New antibiotic therapies for acne and rosacea

Dermatologic Therapy

Volumn 25, Issue 1, 2012, Pages 23-37

  Mays, Rana Majd ^a   Gordon, Rachel A ^a   Wilson, Janice M ^b   Silapunt, Sirunya ^c  

^a Center for Clinical Studies   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

acne; antibiotic; oral; rosacea; topical

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; BAL19403; BENZAMYCIN; BENZOYL PEROXIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; CEFALEXIN; CLENIA; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE PLUS RETINOIC ACID; DAPSONE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; DUAC; EPIGALLOCATECHIN GALLATE; ERYTHROMYCIN; LEVOFLOXACIN; LYMECYCLINE; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; NADIFLOXACIN; NB003; OMIGANAN; PLACEBO; ROXITHROMYCIN; SULFACETAMIDE PLUS SULFUR; TAURINE BROMAMINE; TETRACYCLINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACNE VULGARIS; AGRANULOCYTOSIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BLOOD BRAIN BARRIER; BRAIN PSEUDOTUMOR; BREAST FEEDING; CELL MIGRATION; CHRONIC PERIODONTITIS; DECREASED APPETITE; DERMATITIS HERPETIFORMIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; ENTERIC COATED TABLET; ERYTHEMA; ESOPHAGITIS; EVENING DOSAGE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; IN VITRO STUDY; INFLAMMATION; LEPROSY; LIPOPHILICITY; LOW DRUG DOSE; LUPUS LIKE SYNDROME; METHEMOGLOBINEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPHIL; NONHUMAN; PATIENT COMPLIANCE; PEMPHIGUS VULGARIS; PHOTOSENSITIVITY; PREGNANCY; PROPIONIBACTERIUM ACNES; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; ROSACEA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINUSITIS; SKIN ABRASION; SKIN BURNING SENSATION; SKIN DISCOLORATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN PRURITUS; SKIN TINGLING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PYOGENES; SYSTEMIC THERAPY; TABLET FORMULATION; TASTE DISORDER; TELANGIECTASIA; THRUSH; TREATMENT DURATION; VAGINA CANDIDIASIS; VERTIGO; VOMITING;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; INFLAMMATION; ROSACEA;

EID: 84861306901     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01497.x     Document Type: Article

References (84)

1. Kurokawa I, Danby FW, Ju Q, et al,. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009: 18 (10): 821-832.
2. Farrar MD, Ingham E,. Acne: inflammation. Clin Dermatol 2004: 22 (5): 380-384.
3. Webster GF, Graber EM,. Antibiotic treatment for acne vulgaris. Semin Cutan Med Surg 2008: 27 (3): 183-187.
4. Gollnick H,. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003: 63 (15): 1579-1596.
5. Monk E, Shalita A, Siegel DM,. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011: 63 (2): 130-145.
6. Skidmore R, Kovach R, Walker C, et al,. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003: 139 (4): 459-464.
7. Katsambas AD, Stefanaki C, Cunliffe WJ,. Guidelines for treating acne. Clin Dermatol 2004: 22 (5): 439-444.
8. Sapadin AN, Fleischmajer R,. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006: 54 (2): 258-265.
9. Krautheim A, Gollnick HP,. Acne: topical treatment. Clin Dermatol 2004: 22 (5): 398-407.
10. Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ,. Antibiotics, acne, and Staphylococcus aureus colonization. Arch Dermatol 2011: 147 (8): 917-921.
11. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ,. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003: 139 (4): 467-471.
12. Thiboutot D,. Dermatologists do not yet fully understand the clinical significance of antibiotic use and bacterial resistance in patients with acne: comment on "Antibiotics, acne, and Staphylococcus aureus colonization." Arch Dermatol 2011: 147 (8): 921-922.
13. Webster GF,. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol 2010: 9 (5): 532-536.
14. Kircik LH,. Harnessing the anti-inflammatory effects of topical dapsone for management of acne. J Drugs Dermatol 2010: 9 (6): 667-671.
15. Imahiyerobo-Ip JI, Dinulos JG,. Changing the topography of acne with topical medications. Curr Opin Pediatr 2011: 23 (1): 121-125.
16. Schlessinger J, Menter A, Gold M, et al,. ZIANA Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007: 6 (6): 607-615.
17. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A,. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000: 143 (3): 498-505.
18. Jackson JM, Fu JJ, Almekinder JL,. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol 2010: 9 (2): 131-136.
19. Leyden JJ, Krochmal L, Yaroshinsky A,. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006: 54 (1): 73-81.
20. Richter JR, Forstrom LR, Kiistala UO, Jung EG,. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998: 11 (3): 227-233.
21. Leyden J, Wortzman M, Baldwin EK,. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol 2009: 8 (4): 383-388.
22. Lookingbill DP, Chalker DK, Lindholm JS, et al,. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997: 37 (4): 590-595.
23. Bikowski JB,. Clinical experience results with clindamycin 1% benzoyl peroxide 5% gel (Duac) as monotherapy and in combination. J Drugs Dermatol 2005: 4 (2): 164-171.
24. Langner A, Chu A, Goulden V, Ambroziak M,. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol 2008: 158 (1): 122-129.
25. Dosik JS, Vamvakias G,. Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers. Am J Clin Dermatol 2008: 9 (5): 313-317.
26. Seidler EM, Kimball AB,. Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. J Am Acad Dermatol 2011: 65 (4): e117-e119.
27. Taylor GA, Shalita AR,. Benzoyl peroxide-based combination therapies for acne vulgaris: a comparative review. Am J Clin Dermatol 2004: 5 (4): 261-265.
28. Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF,. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001: 5 (1): 37-42.
29. Thiboutot D, Jarratt M, Rich P, Rist T, Rodriguez D, Levy S,. A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clin Ther 2002: 24 (5): 773-785.
30. Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A,. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008: 7 (12): 1149-1152.
31. Kircik LH,. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol 2010: 9 (11): 1407-1411.
32. Berger RS,. A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol 1988: 28 (4): 367-370.
33. Jarvinen A, Nykanen S, Paasiniemi L, Hirsjaervi-Lahti T, Mattila J,. Enteric coating reduces upper gastrointestinal adverse reactions to doxycycline. Clin Drug Investig 1995: 10: 323-327.
34. Del Rosso JQ, Garner SE,. Commentaries on "Minocycline for acne vulgaris: efficacy and safety" with a response from the review authors. Evid Based Child Health 2011: 6 (5): 1547-1549.
35. Del Rosso JQ,. Weight-based dosing and extended-release formulation of minocycline tablets: is there clinical significance? J Clin Aesthet Dermatol 2009: 2 (1): 44-47.
36. Rafiei R, Yaghoobi R,. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat 2006: 17 (4): 217-221.
37. Kus S, Yucelten D, Aytug A,. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005: 30 (3): 215-220.
38. Kapadia N, Talib A,. Acne treated successfully with azithromycin. Int J Dermatol 2004: 43 (10): 766-767.
39. Amin K, Riddle CC, Aires DJ, Schweiger ES,. Common and alternate oral antibiotic therapies for acne vulgaris: a review. J Drugs Dermatol 2007: 6 (9): 873-880.
40. Fernandez-Obregon AC,. Azithromycin for the treatment of acne. Int J Dermatol 1997: 36 (3): 239-240.
41. Antonio JR, Pegas JR, Cestari TF, Do Nascimento LV,. Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety. J Dermatolog Treat 2008: 19 (4): 210-215.
42. Parsad D, Pandhi R, Nagpal R, Negi KS,. Azithromycin monthly pulse vs. daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001: 28 (1): 1-4.
43. Singhi MK, Ghiya BC, Dhabhai RK,. Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris. Indian J Dermatol Venereol Leprol 2003: 69 (4): 274-276.
44. Babaeinejad S, Khodaeiani E, Fouladi RF,. Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age? J Dermatolog Treat 2011: 22 (4): 206-210.
45. Gruber F, Grubisic-Greblo H, Kastelan M, Brajac I, Lenkovic M, Zamolo G,. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa. J Chemother 1998: 10 (6): 469-473.
46. Bardazzi F, Savoia F, Parente G, et al,. Azithromycin: a new therapeutical strategy for acne in adolescents. Dermatol Online J 2007: 13 (4): 4.
47. Innocenzi D, Skroza N, Ruggiero A, Concetta Potenza M, Proietti I,. Moderate acne vulgaris: efficacy, tolerance and compliance of oral azithromycin thrice weekly for. Acta Dermatovenerol Croat 2008: 16 (1): 13-18.
48. Elewski BE,. A novel treatment for acne vulgaris and rosacea. J Eur Acad Dermatol Venereol 2000: 14 (5): 423-424.
49. González R, Welsh O, Ocampo J, et al,. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico. Int J Dermatol 2010: 49 (9): 1003-1007.
50. Parish LC, Parish JL, Routh HB, Witkowski JA,. The treatment of acne vulgaris with low dosage doxycycline. Acta Dermatovenerol Croat 2005: 13 (3): 156-159.
51. Fenner JA, Wiss K, Levin NA,. Oral cephalexin for acne vulgaris: clinical experience with 93 patients. Pediatr Dermatol 2008: 25 (2): 179-183.
52. Sheeler RD,. Cephalosporin for acne vulgaris. J Am Acad Dermatol 1986: 14 (6): 1091.
53. Kawada A, Aragane Y, Tezuka T,. Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: an open study. Dermatology 2002: 204 (4): 301-302.
54. Dreier J, Amantea E, Kellenberger L, Page MG,. Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes. Antimicrob Agents Chemother 2007: 51 (12): 4361-4365.
55. Heller S, Kellenberger L, Shapiro S,. Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic. Antimicrob Agents Chemother 2007: 51 (6): 1956-1961.
56. Pannu J, McCarthy A, Martin A, et al,. In vitro antibacterial activity of NB-003 against Propionibacterium acnes. Antimicrob Agents Chemother 2011: 55 (9): 4211-4217.
57. Marcinkiewicz J, Biedrõn R, Bialecka A, Kasprowicz A, Mak M, Tarqosz M,. Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris. Arch Immunol Ther Exp (Warsz) 2006: 54 (1): 61-68.
58. Marcinkiewicz J, Wojas-Pelc A, Walczewska M, et al,. Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study. Eur J Dermatol 2008: 18 (4): 433-439.
59. Wiesner J, Vilcinskas A,. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010: 1 (5): 440-464.
60. Elsaie ML, Abdelhamid MF, Elsaaiee LT, Emam HM,. The efficacy of topical 2% green tea lotion in mild-to-moderate acne vulgaris. J Drugs Dermatol 2009: 8 (4): 358-364.
61. Mahmood T, Akhtar N, Khan BA, Khan HM, Saeed T,. Outcomes of 3% green tea emulsion on skin sebum production in male volunteers. Bosn J Basic Med Sci 2010: 10 (3): 260-264.
62. Zouboulis CC, Piquero-Martin J,. Update and future of systemic acne treatment. Dermatology 2003: 206 (1): 37-53.
63. Del Rosso JQ,. A status report on the medical management of rosacea: focus ontopical therapies. Cutis 2002: 70 (5): 271-275.
64. Bamford JT,. Rosacea: current thoughts on origin. Semin Cutan Med Surg 2001: 20 (3): 199-206.
65. Webster GF,. Rosacea: pathogenesis and therapy. G Ital Dermatol Venereol 2011: 146 (3): 235-241.
66. Wilkin J,. Rosacea: pat hophysiology and treatment. Arch Dermatol 1994: 130: 359-362.
67. Del Rosso JQ, Baldwin H, Webster G, American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol 2008: 7 (6): 531-533.
68. Del Rosso JQ, Baum EW,. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol 2008: 1 (1): 20-25.
69. Sauder D, Miller R, Gratton D, et al,. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion is demonstrated in a double-blind study. J Dermatol Treat 1997: 8: 79-85.
70. Lebwohl MG, Medansky RS, Russo CL, et al,. The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% lotion and metronidazole 0.75% gel in treatment of rosacea. J Dermatol Treat 1995: 3: 183-185.
71. Davis GF, Glazer SD, Medansky RS,. Successful treatment of rosacea with novel formulation of sodium sulfacetamide 10% and sulfur 5% topical lotion. J Geriatr Dermatol 1994: 18: 553-558.
72. Stweart D,. Assessment of tolerability of a prescription sodium sulfacetamide 10%/sulfur 5% facial cleanser in adult subjects with rosacea. Poster presented at: American Academy of Dermatology 59th Annual Meeting, March 2-7, 2001; Washington, DC. Poster P-148.
73. McClellan KJ, Noble S,. Topical Metronidazole: a review of its use in rosacea. Am J Clin Dermatol 2000: 1 (3): 191-199.
74. Wolf JE Jr,. Medication adherence: a key factor in effective management of rosacea. Adv Ther 2001: 18 (6): 272-281.
75. Pelle MT, Crawford GH, James WD,. Rosacea: II. Therapy. J Am Acad Dermatol 2004: 51: 499-512.
76. Del Rosso JQ,. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother 2004: 5 (1): 5-13.
77. Thiboutot D, Thieroff-Ekerdt R, Graupe K,. Efficacy and safety of azelaic acid 15% gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies. J Am Acad Dermatol 2003: 139: 1444-1450.
78. Elewski BE, Fleischer AB Jr, Pariser DM,. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003: 139 (11): 1444-1450.
79. Del Rosso JQ,. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006: 78 (2): 97-100.
80. Del Rosso JQ, Bikowski J,. Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial results evaluating the effects of 40 mg doxycycline monohydrate controlled-release capsules in treatment of rosacea. J Am Acad Dermatol 2006: 54: (Suppl.): AB30.
81. Del Rosso JQ, Webster GF, Jackson M, et al,. Two randomized, phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007: 65: 791-802.
82. Bikowski JB,. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003: 2 (4): 234-245.
83. Package insert. Oracea. Collagenex Pharmaceuticals, physician's desk reference. 2007.
84. Dahl MV,. Rosacea subtypes: a treatment algorithm. Cutis 2004: 74 (3 Suppl.): 21-27, 32-4.